2 research outputs found
ΠΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΡΡΠΎΠ³Π΅Π½ΠΎΠ² Π² ΡΠΊΠ°Π½ΡΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½ΠΎΠΉ Ρ ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΈ ΡΠ°Π½Π΄Π΅ΠΌΠ½ΠΎΠΉ ΠΌΠ°ΡΡ-ΡΠΏΠ΅ΠΊΡΡΠΎΠΌΠ΅ΡΡΠΈΠΈ
Although estrogen contribution estrogen to breast cancer development is not fully understood, an effective method of their measurement, in the mammary gland might provide additional insight. In this study, we have developed a LC-MS/MS method of simultaneous quantification of estrone and estradiol in breast tissue samples. Analytes were extracted with methyl tert-butyl ether by sonication and derivatized with dansyl chloride. Estrogens were analyzed by liquid chromatography-tandem mass spectrometry with an electrospray ionization source. Accuracy and precision were better than 20% for most concentrations. Although estrone and estradiol levels in normal and malignant breast tissue samples analyzed using our method insignificantly differed. The method developed may be used in further studies aimed at evaluating a role estrogens in breast cancer risk.ΠΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΡΡΡΠΎΠ³Π΅Π½ΠΎΠ² ΡΡΠΈΡΠ°Π΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΡΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° Π΄ΠΎ ΠΊΠΎΠ½ΡΠ° Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Ρ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΡΡΡΠΎΠ³Π΅Π½ΠΎΠ² Π² ΡΠΊΠ°Π½ΡΡ
ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΡΡΡΠΎΠ½Π° ΠΈ ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΡΠΊΠ°Π½ΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π²ΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½ΠΎΠΉ Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ Ρ ΠΌΠ°ΡΡ-ΡΠΏΠ΅ΠΊΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ. ΠΠ½Π°Π»ΠΈΡΡ ΡΠΊΡΡΡΠ°Π³ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΈΠ»-ΡΡΠ΅Ρ-Π±ΡΡΠΈΠ»ΠΎΠ²ΡΠΌ ΡΡΠΈΡΠΎΠΌ Π² ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠΉ Π±Π°Π½Π΅ ΠΈ Π΄Π΅ΡΠΈΠ²Π°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈ Π΄Π°Π½ΡΠΈΠ»Ρ
Π»ΠΎΡΠΈΠ΄ΠΎΠΌ. ΠΡΠ»ΠΈ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ Π²Π°ΡΠΈΠ°Π½ΡΡ Π½ΠΎΡΠΌΠΈΡΠΎΠ²ΠΊΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π΄Π°Π½Π½ΡΡ
Π½Π° ΠΈΡΡ
ΠΎΠ΄Π½ΡΡ ΠΌΠ°ΡΡΡ ΡΠΊΠ°Π½ΠΈ ΠΈ Π½Π° ΠΌΠ°ΡΡΡ ΡΠΊΡΡΡΠ°Π³ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΏΠΈΠ΄ΠΎΠ². Π’ΠΎΡΠ½ΠΎΡΡΡ ΠΈ ΠΏΡΠ΅ΡΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΡΡΡ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π±ΡΠ»ΠΈ Π²ΡΡΠ΅ 20% Π΄Π»Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄Π° Π±ΡΠ»ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΡΠΎΠ²Π½ΠΈ ΡΡΡΡΠΎΠ½Π° ΠΈ ΡΡΡΡΠ°Π΄ΠΈΠΎΠ»Π° Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ Π² Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Π²Π»ΠΈΡΠ½ΠΈΡ ΡΡΡΡΠΎΠ³Π΅Π½Π° Π½Π° ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Molecular genetic prognostic factors for metastatic regional lymph node involvement in breast cancer patients
Objective. To identify molecular genetic prognostic factors for metastatic regional lymph node involvement in breast cancer (BC) on the basis of the gene-expression profiling analysis of primary tumors. Subjects and methods. The investigation enrolled 200 patients with morphologically verified unicentric invasive BC (T1-4N0-3M0,) who had been treated at the Ulyanovsk Regional Clinical Oncology Dispensary in 2012 to 2015. A tumor tissue molecular genetic study was performed using reverse transcription-polymerase chain reaction (RT-PCR) assay; a diagnostic panel consisted of 28 functional genes. Results. In the metastatic regional lymph node involvement group, the primary breast tumor was characterized by enhanced proliferative activity in terms of the expression of the Ki-67 gene (p = 0.028) and by the higher mRNA levels of the NAT (p = 0.039) and CD68 (p <0.001) genes with a reduction in PTEN expression (p <0.001) and with decreased ESR1 gene expression (p = 0.043). A discriminant analysis showed that the accuracy in predicting the presence or absence of metastatic regional lymph node involvement on the basis of a primary tumor molecular genetic study using a 7-gene expression panel was 91.9 and 78.8%, respectively. Conclusion. The primary breast tumor tissue molecular genetic study involving a set of 7 genes (PTEN, CD68, CCNB1, MGB1, MYC, BCL2, and ESR1) can become an additional diagnostic tool for assessing the presence of metastatic lymph node involvement when planning the volume of axillary lymph node dissection in BC patients. Β© 2020, Bionika Media Ltd.. All rights reserved